<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940728-2-00092</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4703 -->  <!-- PJG ITAG l=69 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=41 g=1 f=1 -->  <RINDOCK>[GN  <!-- PJG /ITAG -->  <!-- PJG ITAG l=41 g=6 f=1 --> # <!-- PJG /ITAG -->  <!-- PJG ITAG l=41 g=1 f=1 -->  2260] </RINDOCK> <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=55 g=1 f=1 --> Statement of Organization, Functions, and Delegations of Authority  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Part H, Chapter HF (Food and Drug Administration) of the Statement of Organization, Functions, and Delegations of Authority for the Department of Health and Human Services (35 FR 3685, February 25, 1970, and 56 FR 29484, June 27, 1991, as amended most recently in pertinent part at 58 FR 45111, August 26, 1993) is amended to reflect the establishment of the Office of Women's Health in the Office of External Affairs, Food and Drug Administration (FDA). The organization is being established to facilitate the Agency coordination and communication of women's health issues and initiatives.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> Under Section HF&hyph;B, Organization:  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> 1. Insert a new subparagraph under Office of External Affairs (HFAQ) reading as follows:  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Office of Women's Health.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Serves as the principal advisor to the Commissioner and other key officials on scientific, ethical, and policy issues relating to women's health.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> Provides leadership and policy direction for the Agency regarding issues of women's health and coordinates efforts to establish and advance a women's health agenda for the Agency.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> Monitors the inclusion of women in clinical trials and the implementation of guidelines concerning the representation of women in clinical trials and the completion of gender analysis.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> Identifies and monitors the progress of crosscutting and multidisciplinary women's health initiatives including changing needs, areas that require study, and new challenges to the health of women as they relate to FDA's mission.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> Serves as the Agency's liaison with other agencies, industry, and professional associations with regard to the health of women.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->   <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 --> Dated: July 11, 1994.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <SIGNER> <!-- PJG ITAG l=06 g=1 f=1 --> David A. Kessler,  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNER> <SIGNJOB> <!-- PJG ITAG l=04 g=1 f=1 --> Commissioner of Food and Drugs.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNJOB> <FRFILING> <!-- PJG ITAG l=40 g=1 f=1 --> [FR Doc. 94&hyph;18389 Filed 7&hyph;27&hyph;94; 8:45 am]  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </FRFILING> <BILLING> <!-- PJG ITAG l=68 g=1 f=1 --> BILLING CODE 4160&hyph;01&hyph;M <!-- PJG /ITAG --> </BILLING>  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline -->   <!-- PJG /STAG --></p>
		</main>
</body></html>
            